Abstract: Objective To observe the efficacy and safety of intravenous infusion and pump of rh-endostatin injection (Endostar) combined with paclitaxel puls cisplatin (TP) regimen on patients with advanced ovarian cancer. Methods Thirty-two patients with advanced ovarian cancer confirmed by histopathology or cytopathology were randomly divided into trial group (intravenous pumping+TP, n=16) and control group (intravenous infusion+TP, n=16). The serum VEGF levels and tumor size were measured before and after two cycles, and after four cycles of treatment between both groups, to evaluate the clinical efficacy and safety. Results After two cycles treatment, the effective rate was 37.5% (6/16) and disease control rate was 62.5% (10/16) in the trail group; while those were 25.0% (4/16) and 62.5% (10/16) in the control group(P>0.05). After four cycles treatment, the effective rate was 50.0% (8/16) and disease control rate was 81.3% (13/16) in the trail group; while those were 31.3% (5/16) and 75.0% (12/16) in the control group(P>0.05). The serum VEGF levels in the trial group were lower than that in the control group (P<0.05), and the VEGF levels after four cycles treatment were significantly lower than that after two cycles treatment (P<0.01). The incidence of cardiovascular toxicity and myelosuppression in the trial group were lower than those in the control group, with significant difference(P<0.05). Conclusion The effect of intravenous pumping of Endostar on patients with advanced ovarian cancer is remarkable; it could reduce the S-VEGF level and has lower adverse reaction than intravenous infusion.